Leveraging Immunopeptidomics to Validate Endogenous Antigen Presentation & De-Risk Epitope Selection
Time: 9:00 am
day: Conference Day One
Details:
• Using mass spectrometry-based immunopeptidomics to directly identify MHC-bound peptides from tumor tissue to confirm which predicted antigens are truly presented
• Detecting post-translationally modified, cryptic, or low-abundance peptides that escape standard analysis to overcome predictive blind spots
• Incorporating immunopeptidomics into early discovery workflows to de-risk antigen selection, reduce false positives, and support regulatory confidence in epitope relevance
